Navigation Links
NEBA Health earns patent for integration of NEBA biomarker with clinician's ADHD evaluation
Date:8/15/2013

BOULDER, Colo., Aug. 15, 2013 /PRNewswire/ -- NEBA Health, LLC announces today that Dr. Steven M. Snyder, Research and Development Vice President, has earned US Patent 8,509,884.  The patent protects a key aspect of the NEBA system:  integrating the biomarker with a clinician's workup for ADHD.  "NEBA is not a standalone diagnostic," said Dr. Snyder.  "After the clinician's ADHD evaluation, NEBA helps them determine if the symptoms are due to ADHD or if further testing is warranted."  

"Integrating the NEBA biomarker with a clinician's initial diagnostic impression can bring a clinician's diagnosis more in line with that of multidisciplinary team," said Dr. Snyder.  Research supports that compared to a clinician alone, a multidisciplinary team is better able to determine if ADHD-like symptoms are accounted for by another condition. 

In order to diagnose ADHD, a clinician not only observes criteria regarding behavioral symptoms and impairment, but also must determine whether symptoms would be better accounted for by another condition.  Because ADHD shares symptoms with other disorders, the diagnosis may be difficult.  According to the US Center for Disease Control and Prevention (CDC), 9.5% of all children and adolescents have an ADHD diagnosis.  The ADHD diagnosis rate is increasing.  CDC states that rates of ADHD diagnosis increased an average of 3% per year from 1997 to 2006 and an average of 5.5% per year from 2003 to 2007.

"In their ADHD evaluation, clinicians may be challenged in the current medical environment to determine the primary diagnosis when overlapping symptoms are present," said Howard Merry, President of NEBA Health.  "We are delighted that the USPTO has awarded Dr. Snyder the patent.  It covers NEBA's core technology, and it's another validation point for the 7 years we spent developing and validating NEBA." 

About NEBA Health

NEBA Health has developed the first FDA approved medical device based on brain waves to help assess ADHD.  The device, NEBA, is cleared in the USA (K112711), CE marked, and Health Canada licensed.  To our knowledge, the NEBA FDA validation study is the largest ADHD diagnostic study of this nature ever conducted (275 subjects at 13 clinical sites).  We have ongoing work in ADHD, depression, and dementia.  Our technologies are NIEAAs (Neuropsychiatric Interpretive EEG-based Assessment Aids).  NEBA Health is privately held.


'/>"/>
SOURCE NEBA Health, LLC
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. First students at new College of Pharmacy to begin classes next week at UNT Health Science Center
2. mHealth Identified as Critical Strategy in Medication Adherence Programs
3. iSALUS Healthcare Expands Revenue Cycle Management Services with Billnet Solutions
4. Natus Neurology Incorporated Receives 510(k) & Health Canada Clearance And Launches New Electrodiagnostic System In U.S. & Canada
5. Millennium HealthCare Inc. Featured in Forbes
6. Wolters Kluwer Health Launches Nursing Drug Handbook Specialty Apps
7. PinnacleHealth, Meridian Health Select Perioperative IT from Surgical Information Systems
8. Hospira to Present at the Morgan Stanley Global Healthcare Conference
9. Chinas Strong Economic Growth and Healthcare Investments Generate Success for CPhI
10. Endo and Metamark Announce Sale of HealthTronics Laboratory Solutions
11. Real Time Location Systems (RTLS) Market in Healthcare Industry 2011 - 2015
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... 20, 2017  Palladian Health, a leading provider ... launch of an opioid management program which assists ... and helps stem the growing tide of dependence ... treat chronic non-cancer pain (back pain, neck pain, ... lack of evidence regarding long-term effectiveness. ...
(Date:1/20/2017)... January 20, 2017 Avillion LLP, a co-developer ... Mark Weinberg , MD MBA as Chief Medical Officer. Dr ... USA . ... Dr Weinberg has spent more than 17 years as a ... companies to micro-cap biotech. Over the course of his career, he ...
(Date:1/19/2017)... YORK , Jan. 19, 2017 Report ... Ophthalmic Devices Market? Which areas are going to grow ... potential revenues to 2026, assessing data, trends, opportunities and ... and graphs. Discover the most lucrative areas in the ... lets you assess forecasted sales across the all the ...
Breaking Medicine Technology:
(Date:1/20/2017)... ... January 20, 2017 , ... “Code Word: Chocolate Biscuit”: a biographical account following a man ... is the creation of published author, Marlyn Ivey, born in Lynn Haven, Florida and at ... school and at 19 years of age, he joined the Navy and got married right ...
(Date:1/20/2017)... (PRWEB) , ... January 20, 2017 , ... ... vPEP ® Oscillating Positive Expiratory Pressure (OPEP) device, was featured in a study ... Doug Pursley, MEd, RRT-ACCS, FAARC, “Analysis of Three Oscillating Positive Expiratory Pressure ...
(Date:1/20/2017)... ... ... a beautiful and enchanting tale that teaches children the true meaning of Christmas. “Journey to ... City, and a devoted woman of faith. , “Becoming a parent changes you. In ... my mind for years, but actually doing it might have been a while in coming ...
(Date:1/20/2017)... ... , ... “The Land of More and More”: a brilliant story for ... shares the simple and achievable answer. “The Land of More and More” is the ... Church in Angola, Indiana where he works with the children’s ministry department. , ...
(Date:1/19/2017)... ... 20, 2017 , ... Today, the Centers for Medicare & Medicaid Services (CMS) ... Payment Models (APMs) in 2017. Clinicians who participate in APMs are paid for the ... of the Administration’s effort to build a system that delivers better care and one ...
Breaking Medicine News(10 mins):